Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Receivables - Accured (2023 - 2025)

Century Therapeutics (IPSC) has disclosed Receivables - Accured for 3 consecutive years, with $393000.0 as the latest value for Q4 2025.

  • Quarterly Receivables - Accured fell 68.66% to $393000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $393000.0 through Dec 2025, down 68.66% year-over-year, with the annual reading at $393000.0 for FY2025, 68.66% down from the prior year.
  • Receivables - Accured for Q4 2025 was $393000.0 at Century Therapeutics, down from $1.3 million in the prior quarter.
  • The five-year high for Receivables - Accured was $1.6 million in Q4 2023, with the low at $393000.0 in Q4 2025.
  • Average Receivables - Accured over 3 years is $1.1 million, with a median of $1.2 million recorded in 2023.
  • The sharpest move saw Receivables - Accured dropped 20.13% in 2024, then plummeted 68.66% in 2025.
  • Over 3 years, Receivables - Accured stood at $1.6 million in 2023, then dropped by 20.13% to $1.3 million in 2024, then tumbled by 68.66% to $393000.0 in 2025.
  • According to Business Quant data, Receivables - Accured over the past three periods came in at $393000.0, $1.3 million, and $1.6 million for Q4 2025, Q4 2024, and Q4 2023 respectively.